본문 바로가기

Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3
저널
LEUKEMIA RESEARCH33(11) · pp.1459 · 2009
피인용
Web of Science 5
JCR IF
JCR 2008 2.39
ISSN
0145-2126

저자

  1. 송무곤제1저자부산대학교, 의과대학, 의학과, KO
  2. 정주섭교신저자부산대학교, 의과대학, 의과학과, KO
  3. 설영미부산대학교, 의과대학, 의학과, KO
  4. 김성근부산대학교, 부산대학교병원, 대학병원, KO
  5. 신호진부산대학교, 의과대학, 의학과, KO
  6. 최영진부산대학교, 의과대학, 의학과, KO
  7. 조군제부산대학교, 의과대학, 의학과, KO

초록

imatinib-induced macrocytic anemia was known to result from c-kit inhibition in chronic myeloid leukemia (CML). However, recent studies showed that the prevalence of anemia is increased with high trough imatinib level and increased doses of imatinib influence decreased proliferation of burst forming units-erythroids (BFU-Es). The aim of this study was to evaluate the continuously increased mean cell volume (MCV) level's correlation with cytogenetic response and the favorable outcome in early chronic phase (CP)-CML patients. Clinical importance of MCV level was evaluated to correlate with cytogenetic response and compared with Sokal score, a known excellent prognostic parameter of cytogenetic response (CCR) in 84 early CP-CML patients. The patients with early and continuously increased MCV level irrespective of anemia achieved higher CCR after 12 months of imatinib therapy than patients with non-CCR (p = 0.011). When the value was compared with low Sokal score, elevated MCV was independent predictor of CCR (RR = 12.925, p = 0.002 vs. RR = 35.445, p < 0.001). Furthermore, the patients with early and continuously increased MCV level had a higher probability of maintaining CCR than non-increased level (p = 0.019). Increased MCV level was surrogate marker of achievement and durability to CCR for early CP-CML patients in the present study. (C) 2009 Elsevier Ltd. All rights reserved.

키워드

ImatinibChronic myelogenous leukemiaMean cell volumeCytogenetic responseSokal scoreCHRONIC MYELOGENOUS LEUKEMIACHRONIC-PHASEDOSE-ESCALATIONTHERAPYMESYLATERESISTANCEOVERCOMEFAILURECML

식별자

WoS UID
000269870400007